key: cord-0848577-z6sh2yh4 authors: Ahmed, Sibtain; DeBerardinis, Ralph J.; Ni, Min; Afroze, Bushra title: Vitamin B6-dependent epilepsy due to pyridoxal phosphate-binding protein (PLPBP) defect – First case report from Pakistan and review of literature date: 2020-12-01 journal: Ann Med Surg (Lond) DOI: 10.1016/j.amsu.2020.11.079 sha: d30ea3367f0873cc7632b033bb7833b9c26b1ec5 doc_id: 848577 cord_uid: z6sh2yh4 INTRODUCTION: The Vitamin B6-dependent epilepsies are a heterogeneous group of autosomal recessive disorders usually characterized by neonatal onset seizures responsive to treatment with vitamin B6 available as pyridoxine (PN) or as the biologically active form pyridoxal 5-phosphate (PLP). The vitamin B6–dependent epilepsies are caused by mutations in at least five different genes involved in B6 metabolism. A literature review revealed that only 30 patients with vitamin B6-dependent epilepsy caused by PLPBP mutation have been reported worldwide. PRESENTATION OF CASE: We report a case of baby boy born to first-cousin Pakistani parents who presented with generalized as well as focal seizures starting a few hours after birth and responsive to PLP. Whole exome sequencing revealed a homozygous pathogenic variant NM_007198.4:c.46_47insCA, NP_009129.1:p.Leu17Hisfs, causing a CA duplication resulting in a frameshift in the PLPBP gene. DISCUSSION: Vitamin B6-Dependent Epilepsy due to PLPBP defect is a rare disorder. The developmental outcomes are variable even with early therapy. Few patients are reported to achieve optimal developmental milestones with therapy. PLP has been advocated as the treatment of choice for PLPBP defect, but oral PN has also demonstrated good seizure control in some patients, including ours. CONCLUSION: Vitamin B6-dependent epilepsy due to PLPBP defect is an important differential diagnosis to consider in patients with biochemical features suggestive of pyridoxamine 5′-phosphate Oxidase (PNPO) defect and gene testing can facilitate in reaching the correct diagnosis. Prompt diagnosis and treatment led to excellent seizure control in most patients. The Vitamin B6-dependent epilepsies are a heterogeneous group of autosomal recessive disorders usually characterized by neonatal onset seizures responsive to treatment with vitamin B6 available as pyridoxine (PN) or as the biologically active form of vitamin B6, pyridoxal 5-phosphate (PLP) [1] . PLP serves an essential role for the development of nervous system, owing to its role in neurotransmitter synthesis and as a co-factor for over 160 catalytic enzymes involved in lipid and amino acid metabolism [2] . The vitamin B6-dependent epilepsies are caused by mutations in five genes involved in B6 metabolism. Accumulation of toxic metabolites resulting in inactivation of PLP is caused by Aldehyde Dehydrogenase 7 Family Member A1 (ALDH7A1) (MIM#266100) and Aldehyde Dehydrogenase 4 Family Member A1 (ALDH4A1) (MIM#239510) gene defects. Mutations in pyridoxamine 5 ′ -phosphate Oxidase (PNPO) (MIM#610090) and tissue-nonspecific alkaline phosphatase (TNSALP) (MIM#171760) result in impaired interconversion of B6 vitamers. PLP homeostasis is impaired by defects in pyridoxal phosphate-binding protein (PLPBP) (MIM#604436), previously termed PROSC [2] [3] [4] . PLPBP encodes a PLP homeostasis protein (PLPHP) located in both mitochondria and cytoplasm [5] . PLPHP has a PLP-binding domain and serves as an active transporter of PLP to apo-enzymes, preventing its side reactivity and degradation by intracellular phosphates [4] . The hallmark of pyridoxine-dependent epilepsy is onset of intractable seizures within the first few months of life that are not controlled with antiepileptic drugs but respond both clinically and electrographically to large daily supplements of PN [5] . In the PLPBP defect, neonatal onset seizures are the predominant feature. These seizures do not show much response to treatment with PN, but respond dramatically to PLP. Movement disorders, encephalopathy and hyperglycinemia have also been described in few patients with PLPBP defect [6] . Vitamin B6-dependent epilepsies can be detected by their respective biomarkers and confirmed by molecular testing. Increased levels of threonine and glycine in the cerebrospinal fluid (CSF) suggest a general defect of B6-dependent enzymes [4] . In ALDH7A1 and ALDH4A1 defects, elevated alpha-amino adipic semialdehyde (α-AASA), piperideine-6-carboxylate (P6C), and pipecolic acid concentrations can be detected in the CSF, urine and plasma. In PNPO defect, accumulation of vanillactate in urine and low PLP in CSF are present. TNSALP defect is accompanied by hypophosphatasia. In PLPBP defects, the biochemical phenotype is similar to PNPO defect, making genetic analysis essential to distinguish it from other causes [6] . We searched the MEDLINE and Google Scholar databases for studies with the search terms "vitamin B6-dependent epilepsy" and "PLPBP" or "PLPHP" or "PROSC", without date and language restrictions. The title, abstract and full text of all documents identified according to these search criteria were scrutinized by the authors. Additionally, all references found in the published articles were reviewed for case report ascertainment. The search revealed 6 case reports and case series, including 30 patients with confirmed vitamin B6-dependent epilepsy caused by PLPBP gene defects on molecular analysis [2, 4, [6] [7] [8] [9] [10] . Here we report the first Pakistani patient with PLPBP defect with four years of follow-up. We have also compared the clinical outcome of our patient with thirty reported patients with PLPBP, including their treatment and clinical outcomes. The study was approved by the Institutional Ethics Committee (ERC #2020-4941-10686) and written informed consent was obtained from the parents of the patient for publication of this case report. This work has been reported in line with the Case Report (CARE) guidelines [11] . A baby boy was born to first-cousin Pakistani parents after a term, uncomplicated pregnancy through spontaneous vaginal delivery (SVD). A few hours after birth he was noted to be dull and lethargic. Thirteen hours after birth he began to have both generalized and focal seizures, which were clonic in nature. His dullness persisted and he was referred for a genetics evaluation on the ninth day of life. Family history revealed the death of two siblings with similar presentation during the neonatal period. On examination, the baby was comatose, with no response even upon maximal physical stimulation. The examination was also notable for an absence of neonatal reflexes, severe hypotonia, hyporeflexia of the deep tendon reflexes and a normal anterior fontanalle. The birth length and weight were 49 cm (<25th percentile) and 2.7 kg (10th percentile), respectively. The occipitofrontal circumference (OFC) was recorded as 33.5 cm (between 4th and 0.2nd percentile). A biochemical workup revealed plasma lactate of 5. An electroencephalogram (EEG) showed epileptic discharges, myoclonic jerks and continuous low voltage activity with generalized bursts of sharp transients. Magnetic Resonance Imaging (MRI) of the brain showed differential myelination of the white matter with hyperintensity in subcortical white matter in the frontal lobes. A well-defined cystic area adjacent to the frontal horn of the left ventricle was also noted. MR spectroscopy showed an increased lactate peak with decreased N-acetyl aspartate (NAA). The elevated plasma glycine and marked excretion of vanillactic acid suggested the diagnosis of PNPO defect. Although this disorder is reported to respond to PLP, oral PLP was not immediately available. Oral pyridoxine, 50 mg twice daily, was started on the 11th day of life, and this was replaced with oral PLP 30mg thrice daily when this became available at 1 month of age. The patient showed significant clinical improvement in terms of overall activity, spontaneous eye opening, limb movement, normal crying and active suckling on feeding, all of which were noted even on early oral PN therapy. A repeat EEG was normal. PNPO gene sequencing did not show any sequence change leading us to further explore other genes. Whole exome sequencing revealed a homozygous pathogenic variant NM_007198.4:c.46_47insCA, NP_009129.1:p.Leu17Hisfs, causing a CA duplication resulting into a frameshift in PLPBP. Only one heterozygote for this mutation is present in gnomAD, yielding an allele frequency of 4.81 × 10 − 6 . The baby continued to experience occasional seizures with fever. The oral PLP therapy was interrupted for few weeks at 3.5 years of age due to non-availability of the medicine and he experienced significantly increased seizure frequency without fever, including an admission for status epilepticus. When oral PLP was re-started his seizures were controlled within few hours. At 4 years of age due to the COVID-19 pandemic, the PLP supply chain was interrupted and he was again started on oral pyridoxine 50 mg four times a day. He is also on oral Levetiracetam 100 mg twice daily. At present he is 4 years 5 months old and his seizures are controlled except for occasional brief seizures associated with fever for the last 5 months. His motor and fine motor milestones are age appropriate, but his speech, cognitive functions and social skills are delayed for his age and has an acquired microcephaly, OFC being 48.2 cm (<0.2 percentile). Vitamin B6-Dependent Epilepsy due to PLPBP defect is a rare disorder. A comparison of the age of symptoms onset, clinical manifestations, neuro-imaging findings, treatment regimens, response to therapy and outcome in all thirty-one reported patients with PLPB defect including our patient is summarized in Tables 1 and 2. The PLPBP defect is pan-ethinic as it has been reported from Europe, United States of America, Canada, South East Asia, Western Asia, South Asia, Africa, United Arab Emirates, Syria and India [2, 4, [6] [7] [8] [9] [10] . Both males 19 (61.2%) and females 11 (35.5%) are reported. Gender is not reported for patient number 16. Consanguinity of parents is reported in 21 (68%) patients including ours. The median age of presentation was 2 (IQR: 1-7) days. At the time of these publications, five (16%) patients were deceased, with the age of death ranging from 2 weeks to 4.5 months with a median of 56 days (IQR: 31.5-96.5). PN has to pass through a conversion to PLP to serve as a coenzyme, but PLP is the active coenzyme form of vitamin B6, with better bioavailability as it is able to protect itself from hydrolysis [9] . Responses to therapy in patients with PLPB defects vary in the literature. Darin et al. reported better responses to PLP than PN, whereas Plecko et al. reported that 75% of the patients responded well to PN with prompt cessation of seizures [4, 8] . In 24 (80%) reported patients, PN was used as the first treatment modality, with seizure control achieved in 19 (63%). Six patients (20%) experienced seizure recurrence after PN withdrawal and cessation of seizure after PN reintroduction. In 7 patients (23%), PN was switched to PLP and this resulted in improved seizure control. Two reported patients (12 and 19) received PLP as the initial treatment [2, 9] . In patient 19, whose initial therapy was PLP and adjuvant anti-epileptic drugs, switching PLP to PN did not improve seizure control. This patient subsequently received PN and midazolam Table 1 Demographics, clinical presentation, treatment initiated and neuroimaging findings of cases with PLPB defect including our case (n = 31 (used during acute episodes only) [2] . Our patient experienced breakthrough seizures when treatment was switched from PLP to PN for a few weeks at 3.4 years of age, and this resolved upon re-introduction of PLP. However, a subsequent therapy change to PN at 4 years of age was well tolerated and the child remained seizure free. All of the patients presented with characteristic early neonatal seizures. The median age of treatment initiation with any form of vitamin B6 ranged from an earliest of 4 days to a maximum of 2920 days with a median of 29 days (IQR: 14-65). Of the five deceased patients, only two were treated with PN, but the age of treatment initiation was not mentioned in these patients [4, 8] . The patient reported by Darin et al. developed respiratory depression due to PN and expired at 4.5 months of age [4] . Both motor and cognitive developmental delay (DD) was evident in 14 patients, motor DD alone in 3 cases, and cognitive DD alone in 3 cases. Five patients had age-appropriate developmental milestones and adequate information was not available for the remaining patients. For the patients with age appropriate developmental milestones and optimum seizure control, the age of treatment initiation with PN ranged from 14 to 75 days with a median of 28 days (IQR: 19.5-52). The three cases started on PN within 1 month of age showed good school performances. In our patient treatment with PN was initiated at 11th day of life, despite such early initiation of therapy seizure control was achieved but cognitive development remains sub-optimal. In our patient, elevated plasma glycine and marked excretion of vanillactic acid in UOA impelled a diagnosis of PNPO defect. As the biochemical markers of PNPO, Aromatic L-amino acid decarboxylase deficiency (AADC) and PLPBP defects often overlap and no specific biomarkers have been identified for patients with PLPBP defects, genetic analysis is essential to distinguish it from other causes [6] . The spectrum of the variants in the patients with PLPBP defect is heterogeneous and missense, nonsenses, frameshift and deletions are reported. There is no genotype-phenotype correlation evident from the reported patients as shown in Table 2 . Most of the patients had private familial variant in PLPBP gene. Vitamin B6-dependent epilepsy due to PLPBP defect is an important differential diagnosis to consider in patients with biochemical features suggestive of PNPO defect and gene testing can facilitate in reaching the correct diagnosis. Prompt diagnosis and treatment led to excellent seizure control in most patients. However, the developmental outcomes are variable even with early therapy. Few patients are reported to achieve optimal developmental milestones with therapy. PLP has been advocated as the treatment of choice for PLPBP defect, but oral PN has also demonstrated good seizure control in some patients, including ours. The study was approved by the Institutional Ethics Committee (ERC #2020-4941-10686) written informed consent was obtained from the parents of the patient. Written informed consent was obtained from the parents of the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request. The authors did not receive funding for this project. Not commissioned, externally peer-reviewed. The authors declare that they have no competing interests. The B6 database: a tool for the description and classification of vitamin B6-dependent enzymatic activities and of the corresponding protein families PLPHP deficiency: clinical, genetic, biochemical, and mechanistic insights Treatable newborn and infant seizures due to inborn errors of metabolism Mutations in PROSC disrupt cellular pyridoxal phosphate homeostasis and cause vitamin-B6-dependent epilepsy Pyridoxine-dependent epilepsy Diagnostic pitfalls in vitamin B6-dependent epilepsy caused by mutations in the PLPBP gene Cloning and characterization of human and mouse PROSC (proline synthetase co-transcribed) genes Confirmation of mutations in PROSC as a novel cause of vitamin B 6 -dependent epilepsy PLPBP mutations cause variable phenotypes of developmental and epileptic encephalopathy Diagnostic clarity of exome sequencing following negative comprehensive panel testing in the neonatal intensive care unit The CARE guidelines: consensus-based clinical case reporting guideline development None.